How parents' metabolism in pregnancy relates to the baby's gene markers in gestational diabetes
Studies how both parents' metabolism relates to the baby's epigenetic marks during pregnancy.
Key facts
- Who runs it
- University of Ulm
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 30 Mar 2026
- Expected to end
- 1 Jul 2028
- Type of study
- Observational
- Treatments tested
- Metabolic and epigenetic characterization of parents ans fetuses
- Record updated
- 7 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women between 20 and 28 weeks of pregnancy, together with the father of the child. Both parents must have no known illnesses. The study looks at how the parents' metabolism affects the baby's genes.
- Age
- 18 years and older
- Sex
- Pregnant women and the fathers of their unborn children can join.
- Disease stage
- Women must be between 20 and 28 weeks of pregnancy. No baby abnormalities found in earlier pregnancy checks, ultrasound or NIPT.
- Earlier treatment
- People who take medicines that affect blood sugar (for example steroids, insulin) cannot join. Women who regularly take medicines during pregnancy cannot join.
Main reasons for not taking part
- Type 1 or type 2 diabetes
- Hormone disorders, such as an overactive thyroid or PCOS
- Current depression, other mental health disorders or eating disorders
- Heart or blood vessel disease, or drug or alcohol abuse
- Kidney function (eGFR) < 60 ml/min/1.73 m², C-reactive protein > 10 mg/l, or liver enzymes 2 times above the upper normal level
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Pregnant women between 20 and 28 weeks of gestation
- The father of the child is known and willing to participate in the study
- No known underlying medical conditions in either parent
- No fetal abnormalities detected in first-trimester screening, detailed fetal anatomy ultrasound, non-invasive prenatal testing (NIPT), or any additional prenatal examinations performed, if applicable
- No known underlying diseases
- Understanding and voluntary signing of a consent form before study- related examinations
Who cannot take part
- Regular use of medication during pregnancy
- Drug and/or alcohol abuse
- Type 1 or type 2 diabetes mellitus
- Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
- Current depression or other psychiatric disorders
- Eating disorders
- Pre-existing cardiovascular disease
- Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion
- Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
- Transaminase elevation of 2 times the upper norm
- Age < 18 years
- C-reactive protein > 10 mg/l
- No consent to be informed about incidentally discovered pathological findings
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trials aims to investigate the impact of parental metabolism during pregnancy on fetal epigenetic signatures.
Read full original descriptionShow less
The metabolic profiles of both parents will be evaluated through a blood sample collected from the father and an oral glucose tolerance test administered to the pregnant mother. Additionally, epigenetic signatures will be assessed using parental blood samples. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.
The group in the trial
- Pregnant women + fathers of the unborn child
Metabolic and epigenetic characterization
Treatment: Metabolic and epigenetic characterization of parents ans fetuses
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA
- Plain-language title
- How parents' metabolism in pregnancy relates to the baby's gene markers in gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 7 April 2026